SEC Form SC 13G/A filed by Emergent Biosolutions Inc. (Amendment)
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/30/2024 | $15.00 | Buy | H.C. Wainwright |
8/22/2024 | $16.00 | Buy | Rodman & Renshaw |
3/7/2024 | $5.00 | Hold → Buy | The Benchmark Company |
11/20/2023 | Underweight | JP Morgan | |
8/29/2023 | Buy → Hold | The Benchmark Company | |
4/10/2023 | $22.00 | Hold → Buy | The Benchmark Company |
3/17/2023 | $23.00 → $9.00 | Neutral → Underweight | JP Morgan |
11/10/2022 | Buy → Hold | The Benchmark Company |
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00
The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)